Derek DiRocco - 01 Jun 2022 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Role
Director
Signature
/s/ Jonathan Owen, Attorney-in-fact
Issuer symbol
HOWL
Transactions as of
01 Jun 2022
Net transactions value
$0
Form type
4
Filing time
03 Jun 2022, 16:42:22 UTC
Previous filing
18 May 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOWL Stock Option (right to buy) Award $0 +11,600 $0.000000 11,600 01 Jun 2022 Common Stock 11,600 $3.43 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Remarks:

Exhibit Index: 24.1 Power of Attorney